机构:[1]Department of Clinical Epidemiology and Biostatistics, Peking University People's Hospital, Beijing, China.[2]Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China.[3]National Center for Chronic Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.[4]Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.[5]Chinese Foundation for Hepatitis Prevention and Control, Beijing, China.
National Key R&D Program
of China (2022YFA1303804), National Natural Science Foundation of China (NSFC) (82300660 XXW, 81870406 HYR and
81602939 HXL), Capital’s Funds for Health Improvement and
Research (2020-4-4087 HXL) and Peking University People’s
Hospital Scientific Research Development Funds (RDJP2022-
60).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|3 区医学
小类|3 区胃肠肝病学
最新[2025]版:
大类|3 区医学
小类|3 区胃肠肝病学
第一作者:
第一作者机构:[1]Department of Clinical Epidemiology and Biostatistics, Peking University People's Hospital, Beijing, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Liu Huixin,Wang Xiaoxiao,Wang Lijun,et al.Mortality Burden of Liver Cancer in China: An Observational Study From 2008 to 2020[J].Journal Of Clinical And Translational Hepatology.2024,12(4):371-380.doi:10.14218/JCTH.2023.00455.
APA:
Liu Huixin,Wang Xiaoxiao,Wang Lijun,Yin Peng,Liu Feng...&Rao Huiying.(2024).Mortality Burden of Liver Cancer in China: An Observational Study From 2008 to 2020.Journal Of Clinical And Translational Hepatology,12,(4)
MLA:
Liu Huixin,et al."Mortality Burden of Liver Cancer in China: An Observational Study From 2008 to 2020".Journal Of Clinical And Translational Hepatology 12..4(2024):371-380